Zobrazeno 1 - 10
of 167
pro vyhledávání: '"John W. Hadden"'
Autor:
Ronald G. Coffey, John W. Hadden
Publikováno v:
Stress, Immunity, and Aging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b76d1b5a0d201dab1ae7dca1fb3940e6
https://doi.org/10.1201/9781003065180-22
https://doi.org/10.1201/9781003065180-22
Autor:
Wolf Herve Fridman, Harvey Brandwein, Neil L. Berinstein, J. Michael White, Cécile Badoual, James E. Egan, Lorraine Baltzer, Lynn C. Goldstein, Adel K. El-Naggar, Theresa L. Whiteside, John W. Hadden, Paul H. Naylor, Gregory T. Wolf
Publikováno v:
Cancer Immunology, Immunotherapy. 61:771-782
Twenty-seven subjects with squamous cell cancer of the head and neck received the neoadjuvant IRX-2 immunotherapy regimen prior to surgery in a Phase 2 trial. Pretreatment tumor biopsies were compared with the primary tumor surgical specimens for lym
Autor:
Jose Luis Barrera Franco, Lorraine Baltzer, Zygmund Roth, Daniel E. Kenady, Scott M. Freeman, Harvey Brandwein, John W. Hadden
Publikováno v:
American Journal of Clinical Oncology. 34:173-178
Objectives Head and neck squamous cell carcinoma (HNSCC) is associated with profound defects in cellular immunity. IRX-2, a primary cell-derived biologic containing multiple cytokines, has enhanced immune responses and induced tumor rejection in prec
Autor:
Paul H. Naylor, John W. Hadden
Publikováno v:
Annals of the New York Academy of Sciences. 1194:162-168
Thymosin alpha1 (Talpha1) is a 28 amino acid biologically active protein with pleiotropic immune enhancing activity. IRX-2 is a primary cell-derived biologic containing multiple cytokines that enhance dendritic cell maturation, promote T-cell growth
Publikováno v:
Annals of the New York Academy of Sciences. 1112:235-244
Thymosin alpha1 (Talpha1) is a 28 amino acid biologically active protein cleaved from positions 2-29 of a precursor protein, prothymosin alpha. Since its discovery, Talpha1 has been administered to animals and humans in a wide variety of settings and
Publikováno v:
International Immunopharmacology. 3:1093-1104
Background : Hematological side effects are not generally expected due to radiotherapy involving limited radiation fields; however, patients with squamous cell carcinoma of the head and neck (SCCH&N) receiving radiation therapy frequently have chroni
Autor:
Jose Luis Barrera, Emma Verastegui, J de la Garza, Elba M. Hadden, Abelardo Meneses, Juan Zinser, John W. Hadden, M Kurman
Publikováno v:
International Immunopharmacology. 3:1073-1081
A Phase II trial in 42 patients with squamous cell cancer of the head and neck (H and NSCC) was performed using a combination immunotherapy with 10-20 days of perilymphatic injections of a natural cytokine mixture (NCM: IRX-2; 200 units IL-2 equivale
Autor:
John W. Hadden
Publikováno v:
International Immunopharmacology. 3:1061-1071
Cellular immunodeficiency is associated with human cancer. Extensive reviews on cancer of the head and neck, lung, esophagus and breast convince the author that for these diseases the immunodeficiency is reasonably well established yet the mechanisms
Autor:
John W. Hadden, Kathy L. Signorelli
Publikováno v:
International Immunopharmacology. 3:1177-1186
Methyl inosine 5'-monophosphate (MIMP) was designed and synthesized in an endeavor to generate compounds with immunostimulatory activity based on the precedent of purines, particularly inosine playing a central role in the development and function of